Delay of insulin addition to oral combination therapy despite inadequate glycemic control: Delay of insulin therapy

Journal of General Internal Medicine

Volumn 22, Issue 4, 2007, Pages 453-458

  Nichols, Gregory A ^a   Koo, Yuri H ^b   Shah, Sonali N ^b  

^a CENTER FOR HEALTH RESEARCH   (United States)

^b PFIZER INC   (United States)

Author keywords

Glycemic control; Insulin; Oral combination therapy

Indexed keywords

HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEALTH CARE PLANNING; HUMAN; INSULIN TREATMENT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; THERAPY DELAY; TREATMENT WITHDRAWAL; BLOOD; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; GLUCOSE BLOOD LEVEL; GLYCEMIC INDEX; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; RETROSPECTIVE STUDY; TIME;

ADMINISTRATION, ORAL; AGED; BLOOD GLUCOSE; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLYCEMIC INDEX; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 34250209915     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-007-0139-y     Document Type: Article

References (29)

1. UKPDS Group. Glycemic control with diet, sulphonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005-12.
2. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-86.
3. UKPDS Group. UKPDS 33: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes. Lancet. 1998;352:837-51.
4. UKPDS Group. UKPDS 34: Effect of intensive blood-glucose control with metformin on complications on overweight patients with type 2 diabetes. Lancet. 1998;352:854-65.
5. Boccuzzi SJ, Wogen J, Fox J, Sung JCY, Shah AB, Kim J. Utilization of oral antihyperglycemic agents in a drug-insured US population. Diabetes Care. 2001;24:1411-15.
6. Brown JB, Nichols GA. Slow response to loss of glycemic control in type 2 diabetes mellitus. Am J Manag Care. 2003;9:213-17.
7. Cook MN, Girman CJ, Stein PP, Alexander CM, Holman RR. Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care. 2005;28:995-1000.
8. De Witt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: a scientific review. JAMA. 2003;289:2254-64.
9. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2006;29:1963-72.
10. Shah BR, Hux JE, Laupacis A, Zinman B, van Walraven C. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care. 2005;28:600-06.
11. Grant RW, Cagliero E, Dubey AK, et al. Clinical inertia in the management of type 2 diabetes metabolic risk factors. Diabet Med. 2004;21:150-5.
12. Grant RW, Buse JB, Meigs JB, The University HealthSystem Consortium (UHC) Diabetes Benchmarking Project Team. Quality of diabetes care in U.S. academic medical centers. Diabetes Care. 2005;28:337-42.
13. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005;28:2543-5.
14. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28:2673-9.
15. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004;27:1535-40.
16. Hertz RP, Unger AN, Lustik MB. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance. Clin Ther. 2005;27:1064-73.
17. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105-16.
18. American Diabetes Association. Standards of medical care for patients with diabetes mellitus; clinical practice recommendations 2006. Diabetes Care. 2006;29:S1-S85.
19. Stratton IM, Alder AI, Neil HAW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR, and on behalf of the UKPDS Study Group. UKPDS 35: association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 8-12-2000;21[7258], 405-12.
20. Leslie CA, Satin-Rapaport W, Matheson D, Stone R, Enfield G. Psychological insulin resistance: a missed diagnosis? Diabetes Spectr. 1994;7:52-7.
21. Rubin R, Peyrot M. Psychological issues and treatments in people with diabetes. J Clin Psychol. 2001;57:457-78.
22. Koerbel G, Korytkowski M. Insulin therapy resistance: another form of insulin resistance in type 2 diabetes. Pract Diabetol. 2003;22:36-40.
23. Peyrot M. Psychological insulin resistance: overcoming barriers to insulin therapy. Pract Diabetol. 2004;23:6-12.
24. Polonsky WH, Jackson RA. What's so tough about taking insulin? Addressing the problem of psychological insulin resistance in type 2 diabetes. Clin Diabetes. 2004;22:147-50.
25. Nichols GA, Alexander CM, Girman CJ, Kamal-Bahl S, Brown JB. Treatment escalation and rise in HbA1c following successful initial Metformin therapy. Diabetes Care. 2006;29:504-9.
26. Nichols GA, Alexander CM, Girman CJ, Kamal-Bahl S, Brown JB. A contemporary analysis of secondary failure of successful sulfonylurea therapy. Endocr Pract. 2006; (in press).
27. Brown JB, Nichols GA, Glauber HS. Case-control study of 10 years of comprehensive diabetes care. West J Med. 2000;172:85-90.
28. Nichols GA, Glauber HS, Javor K, Brown JB. Achieving further glycemic control in type 2 diabetes mellitus. West J Med. 2000;173:5-9.
29. Willey CJ, Andrade SE, Cohen J, Fuller JC, Gurwitz JH. Polypharmacy with oral antidiabetic agents: an indicator of poor glycemic control. Am J Manag Care. 2006;12:435-440.